The blood moon phase will be visible across swathes of North America before dawn on March 3. On March 3, billions of people ...
An international study has revealed a surprising connection between quantum physics and the theoretical models underlying ...
Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.
The ET Make in India SME Regional Summit in Vadodara on February 20 drew strong industry participation, highlighting the resilience of the region’s MSME ecosystem.
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) ...
PureHealth introduces pilot phase of “Nada”, an AI-based tool to assist doctors in documenting medical notes during patient visits (Photo: AETOSWire) Developed specifically for use during clinical ...
Hosted on MSN
PureHealth introduces pilot phase of 'Nada' AI-based tool to assist doctors in documenting medical notes
ABU DHABI, 29th December, 2025 (WAM) -- PureHealth, the largest healthcare group in the Middle East, has announced the launch of the pilot phase of “Nada”, an AI-powered service that functions as a ...
ABU DHABI, United Arab Emirates, December 29, 2025--(BUSINESS WIRE)--PureHealth, the largest healthcare group in the Middle East, has announced the launch of the pilot phase of "Nada", an AI-powered ...
Abu Dhabi: PureHealth, the largest healthcare group in the Middle East, has announced the launch of the pilot phase of “Nada”, an AI-powered service that functions as a secure digital assistant, ...
Digital asset treasuries were flying high this year until bitcoin's sudden October crash. Now, many of those companies are sitting on unrealized losses. Over 180 public companies currently hold crypto ...
MELBOURNE, Australia, Dec. 15, 2025 /PRNewswire/ -- Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announces that the ACTION3 Phase 3 ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results